Andere Sprachen Olema Pharmaceuticals, Inc.

Aktien

A2QGWT

US68062P1066

OLMA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
10,67 ^USD	+5,96 %		+7,24 %	-23,95 %

02.04.	OLEMA PHARMACEUTICALS, INC. : Von Goldman Sachs zum Kaufen aufgerüstet	ZM
12.03.	OLEMA PHARMACEUTICALS, INC. : Bewertung von HC Wainwright kaufen	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02.05.
Olema Oncology to Participate in Upcoming Investor Conferences in May	01.05.
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference	08.04.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02.04.
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to S&P Biotechnology Select Industry Index	18.03.
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	11.03.
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update	11.03.
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	11.03.
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors	06.03.
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors	06.03.
Olema Oncology Announces Publication of Data Highlighting Palazestrant?s Ability to Inhibit Wild-Type and Mutant Er+ Breast Cancer Both as Monotherapy and in Combination with Cdk4/6 Inhibitors	06.03.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04.03.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04.03.
Olema Oncology to Participate in Upcoming Investor Conferences	06.02.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02.02.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02.02.
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate	08.01.
Olema Pharmaceuticals, Inc. Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate	08.01.
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference	02.01.
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to NASDAQ Biotechnology Index	18.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Olema Pharmaceuticals, Inc.

Aktien

A2QGWT

US68062P1066

OLMA

Andere Sprachen

Filter